Shares of Introgen Therapeutics Inc. plummeted 38.7 percent Tuesday after the firm said the FDA refused to accept the biologics license application for its gene therapy Advexin as a treatment of recurrent, refractory head and neck cancer. (BioWorld Today) Read More
